Romano Brothers & Co’s Kyntra Bio KYNB Stock Holding History

Romano Brothers & Co’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28	Closed	-$11.2K	–	523
2022 Q4	$11.2K	Buy	+28	New	+$10.7K	﹤0.01%	713

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Romano Brothers & Co's KYNB Position: Q1 2023 in Review

Romano Brothers & Co sold out of Kyntra Bio (KYNB) in Q1 2023, closing a stake of 28 shares — an estimated $11.2K sold.

Romano Brothers & Co first reported a position in KYNB in Q4 2022 and held it in 1 quarter. The position peaked at $11.2K in Q4 2022. 171 funds tracked by Wall St. Rank hold KYNB as of Q1 2023.

Romano Brothers & Co reported no remaining Kyntra Bio position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 28 Kyntra Bio shares in Q1 2023, an estimated $11.2K.
Romano Brothers & Co first reported a position in Kyntra Bio in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Kyntra Bio position peaked at $11.2K in Q4 2022.
171 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.